Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @jaybradner
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @jaybradner
-
Thanks for everything you do in
#globalhealth and#drugdiscovery,@SueDHellmann. Read more in her wonderful Q&A with questions submitted by@statnews readershttps://www.statnews.com/2020/01/21/qa-gates-foundation-ceo-sue-desmond-hellmann/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The high mutational burden of smoking in non-malignant lung airway cells. Terrifying
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
An exciting update on our Cancer Cell Line Encyclopedia: Quantified proteome profiles for 375 cell lines in
@CellCellPress.@NovartisSciencehttps://www.cell.com/cell/fulltext/S0092-8674(19)31385-6#%20 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CAN’T. STOP. ROTATING. The human SWI/SNF complex at 3.7 A resolution, bound to a nucleosome, complements of Yanhui Xu and
@sciencemagazine.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jay Bradner, M.D. proslijedio/la je Tweet
“This is what happens when a structural biologist starts hanging around with a bunch of kinase-obsessed genetic screeners and cell signaling geeks!”
@CMJohannessenHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Phil’s mission is the NIBR mission – to innovate strategically so that we can fulfill our promise to help bring new medicines to patients efficiently
#JPM20Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Ambition is not something we shy away from in our journey to bring innovative medicines to patients. 2020 will be no different—here’s how:https://twitter.com/NovartisScience/status/1215293178821169152 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Touching story that’s moving as a researcher & a parent. Thank you for sharing the story behind the
#BlindChickenMoleculehttps://twitter.com/NatureChemistry/status/1202989136879206400 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
I’m interested to hear what others in the scientific community think will be the biggest stories of 2020.
@sciencemagazine shares their list here:https://www.sciencemag.org/news/2020/01/science-stories-likely-make-headlines-2020 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Helpful discussion on the importance of permeability in targeted protein degradation, based on recent work out of UNC.
@Dereklowe blog in@ScienceTM:Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
So cool to see Lynn Hershman Leeson’s “Anti-Bodies” listed as one of the “Best Art Books of 2019” in
@nytimes. Fun fact: the LYNNHERSHMAN antibody grew out of an art-science collaboration w/ Thomas Huber at NIBR-Basel.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thank you
@FierceBiotech for your generous consideration highlighting@Novartis' accomplishments in 2019. Well done to all those who contributed to getting much needed drugs to the finish line!https://twitter.com/FierceBiotech/status/1212736529057140737 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
“Investment in open
#datascience can promote resilient workflows and reinforce a culture of inclusion, trust and innovation.” More in Nature:#opensciencehttps://www.nature.com/articles/d41586-019-03335-4 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lovely
@bostonherald piece on Bill Kaelin, his work, and its potential impact on patients.https://www.bostonherald.com/2019/12/14/harvard-nobel-prize-winners-research-extends-life-of-cancer-patient/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Fun
#tweetorial on recent NIBR work investigating DCAF15’s potential in#TPD. Includes a brief explainer re: molecular glue degraders, for the curious.https://twitter.com/NovartisScience/status/1205524535132471302 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The latest research on our CDK4/6 inhibitor in metastatic breast cancer, discovered
@NovartisScience, is now available in@NEJM. Study shows targeted therapy could potentially help some women with a particular type of aggressive#breastcancer live longerHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
It was a pleasure to talk about next-gen cancer therapeutics last week with the folks
@mit_hst@harvardmed. Thanks for the invite!
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Encouraging Phase 1 performance of our home grown, allosteric ABL in today's
@NEJM. Allostery, oncogenes and overcoming resistance, all specialities of the house.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.